Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

82.78USD
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
$82.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,213,252
52-wk High
$84.26
52-wk Low
$59.81

Latest Key Developments (Source: Significant Developments)

IBM, KPMG, Merck And Walmart in blockchain collaboration with FDA
Thursday, 13 Jun 2019 

June 13 (Reuters) - Walmart Inc ::IBM, KPMG, MERCK AND WALMART TO COLLABORATE AS PART OF FDA'S PROGRAM TO EVALUATE THE USE OF BLOCKCHAIN TO PROTECT PHARMACEUTICAL PRODUCT INTEGRITY.IBM - PILOT PROJECT IS SCHEDULED TO BE COMPLETED IN Q4 OF 2019.IBM - BLOCKCHAIN MAY BE INTEGRATED WITH EXISTING SUPPLY CHAIN AND TRACEABILITY SYSTEMS.IBM - PROGRAM IS TO ASSIST DRUG SUPPLY CHAIN STAKEHOLDERS IN DEVELOPING A SYSTEM THAT WILL IDENTIFY, TRACE CERTAIN PRESCRIPTION DRUGS DISTRIBUTED IN U.S..  Full Article

Merck Says Keytruda Showed Improved Overall Survival In Head & Neck Cancer Trial
Friday, 31 May 2019 

May 31 (Reuters) - Merck & Co Inc ::MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DEMONSTRATES IMPROVED OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AT FINAL ANALYSIS OF PIVOTAL PHASE 3 KEYNOTE-048 TRIAL.MERCK & CO - FOR DUAL PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL, STATISTICAL SIGNIFICANCE NOT ACHIEVED FOR KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY IN CPS≥20 POPULATION VERSUS EXTREME REGIMEN.MERCK & CO - FOR CPS ≥1 POPULATION KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 35% IN THESE PATIENTS, WITH SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.MERCK & CO - KEYTRUDA WITH CHEMOTHERAPY REDUCED RISK OF DEATH BY 40% IN PATIENTS WHOSE TUMORS EXPRESSED PD-L1 WITH CPS≥20, SHOWING SIGNIFICANTLY LONGER OS VERSUS EXTREME REGIMEN.  Full Article

Zymeworks Earns Milestone Payment In Merck Collaboration
Wednesday, 29 May 2019 

May 29 (Reuters) - Zymeworks Inc ::ZYMEWORKS EARNS MILESTONE PAYMENT IN MERCK COLLABORATION.ZYMEWORKS - UNDER TERMS, CO GRANTED MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, DEVELOP & COMMERCIALIZE CERTAIN BISPECIFIC THERAPEUTIC CANDIDATES.ZYMEWORKS - UNDER TERMS, CO IS ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON PRODUCT SALES.ZYMEWORKS INC - WILL RECEIVE US$2.0 MILLION IN CONNECTION WITH MERCK'S COMPLETION OF A LATE-STAGE PRECLINICAL STUDY FOR A BISPECIFIC ANTIBODY CANDIDATE.  Full Article

Merck Sets Quarterly Dividend Of $0.55 Per Share
Tuesday, 28 May 2019 

May 28 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.55PER SHARE.  Full Article

Merck To Acquire Peloton Therapeutics For An Upfront Payment Of $1.05 Billion In Cash
Tuesday, 21 May 2019 

May 21 (Reuters) - Merck & Co Inc ::MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK & CO INC - MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH.MERCK & CO INC - WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH..MERCK & CO - PELOTON SHAREHOLDERS ELIGIBLE TO RECEIVE FURTHER $1.15 BILLION CONTINGENT UPON SUCCESSFUL ACHIEVEMENT OF FUTURE MILESTONES FOR CERTAIN CANDIDATES.MERCK & CO INC - ACQUISITION INCLUDES NOVEL LATE-STAGE RENAL CELL CARCINOMA CANDIDATE, PT2977.MERCK & CO INC - COMPANIES ANTICIPATE ACQUISITION WILL CLOSE IN Q3 OF 2019.  Full Article

Third Point LLC Dissolves Share Stake In Merck & Co Inc
Wednesday, 15 May 2019 

May 15 (Reuters) - Third Point LLC::THIRD POINT LLC DISSOLVES SHARE STAKE IN MERCK & CO INC.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Moderna Says Merck Has Elected To Conduct A Phase 1 Clinical Trial For mRNA-1172
Wednesday, 8 May 2019 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MODERNA INC - MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck Announces Results From Mid-Stage Trial Of Investigational 15-Valent Pneumococcal Conjugate Vaccine
Wednesday, 8 May 2019 

May 8 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES RESULTS FROM PHASE 2 TRIAL OF INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) IN INFANTS.MERCK & CO INC - V114 MET PRIMARY ENDPOINT BY DEMONSTRATING NONINFERIORITY TO PCV13 FOR ALL SHARED SEROTYPES, AND AN IMMUNE RESPONSE FOR TWO ADDITIONAL SEROTYPES.MERCK & CO INC - DATA SUPPORT CONTINUED PROGRESSION OF PHASE 3 STUDIES WITH V114.  Full Article

Moderna Inc Entered Into A Fifth Amendment To Collaboration And License Agreement With Merck Sharp & Dohme Corp
Wednesday, 8 May 2019 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck’S Belsomra (Suvorexant) C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial
Tuesday, 7 May 2019 

May 7 (Reuters) - Merck & Co Inc ::MERCK’S BELSOMRA® (SUVOREXANT) C-IV MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL FOR THE TREATMENT OF INSOMNIA IN PEOPLE WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE DEMENTIA.MERCK & CO INC - DATA TO BE FILED WITH FDA FOR POTENTIAL INCLUSION IN BELSOMRA PRESCRIBING INFORMATION.MERCK & CO INC - ADVERSE EVENTS WERE RECORDED IN 22.5% (N=32/142) OF PATIENTS IN BELSOMRA GROUP AND 16.1% (N=23/143) IN PLACEBO GROUP.MERCK & CO INC -IN TRIAL, BELSOMRA MET ITS PRIMARY AND SECONDARY EFFICACY ENDPOINTS.MERCK & CO INC - ONE PATIENT IN EACH GROUP DISCONTINUED TREATMENT DUE TO AN ADVERSE EVENT.  Full Article

Photo

Ebola's spread shows how science needs societies to succeed

LONDON - The persistence of Congo's Ebola outbreak and its deadly spread to Uganda in recent days show how societal issues are as crucial as scientific advances in controlling disease outbreaks, specialists in global public health say.